23 results on '"Quiroga, Borja"'
Search Results
2. Estrategias de prevención y tratamiento de la infección por SARS-CoV-2 (Severe Acute Respiratory Coronavirus 2) en pacientes con enfermedad renal crónica: revisión de la literatura.
- Author
-
Marques Vida, María, Muñez Rubio, Elena, Quiroga, Borja, Montejano, Rocío, Morales, Enrique, and Javier Candel, Francisco
- Abstract
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
3. From cardiorenal syndromes to cardionephrology: a reflection by nephrologists on renocardiac syndromes
- Author
-
Quiroga, Borja, Ortiz, Alberto, Navarro-Gonzalez, Juan F., Santamaria, Rafael, de Sequera, Patricia, Diez, Javier, Spanish Soc Nephrology, [Quiroga, Borja] Hosp Univ la Princesa, Nephrol Dept, IIS La Princesa, Madrid, Spain, [Ortiz, Alberto] Univ Autonoma Madrid, Fdn Jimenez Diaz, Dept Med, Div Nephrol IIS, Madrid, Spain, [Ortiz, Alberto] Carlos III Inst Hlth, RICORS2040, Madrid, Spain, [Santamaria, Rafael] Carlos III Inst Hlth, RICORS2040, Madrid, Spain, [Navarro-Gonzalez, Juan F.] Univ La Laguna, Univ Hosp Nuestra Senora de Candelaria, Div Nephrol, Santa Cruz De Tenerife, Spain, [Navarro-Gonzalez, Juan F.] Univ La Laguna, Univ Hosp Nuestra Senora de Candelaria, Res Unit, Santa Cruz De Tenerife, Spain, [Navarro-Gonzalez, Juan F.] Univ Inst Biomed Technol, Santa Cruz De Tenerife, Spain, [Navarro-Gonzalez, Juan F.] Univ Hosp Reina Sofia, Div Nephrol, Cordoba, Spain, [Santamaria, Rafael] Univ Hosp Reina Sofia, Div Nephrol, Cordoba, Spain, [Santamaria, Rafael] Maimonides Biomed Res Inst Cordoba IMIBIC, Cordoba, Spain, [de Sequera, Patricia] Univ Complutense Madrid, Univ Hosp Infanta Leonor, Dept Nephrol, Madrid, Spain, [Diez, Javier] Univ Navarra, Ctr Appl Med Res, Pamplona, Spain, [Diez, Javier] Univ Navarra, Sch Med, Pamplona, Spain, and [Diez, Javier] Carlos III Inst Hlth, Ctr Invest Biomed Red Enfermedades Cardiovasc CIB, Madrid, Spain
- Subjects
Coronary flow reserve ,Heart-failure ,renocardiac syndromes ,cardionephrology ,Inflammatory cytokines ,Cardiovascular events ,Growth-factor 23 ,Soluble tweak ,acute kidney injury ,cardiorenal syndromes ,Chronic kidney-disease ,Pulmonary-hypertension ,Mild renal-insufficiency ,Trimethylamine-n-oxide ,chronic kidney disease - Abstract
Cardiorenal syndromes (CRS) are broadly defined as disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other. CRS are currently classified into five categories, mostly based on disease-initiating events and their acuity or chronicity. CRS types 3 and 4 (also called renocardiac syndromes) refer to acute and chronic kidney dysfunction resulting in acute and chronic heart dysfunction, respectively. The notion of renocardiac syndromes has broadened interest in kidney-heart interactions but uncertainty remains in the nephrological community's understanding of the clinical diversity, pathophysiological mechanisms and optimal management approaches of these syndromes. This triple challenge that renocardiac syndromes (and likely other cardiorenal syndromes) pose to the nephrologist can only be faced through a specific and demanding training plan to enhance his/her cardiological scientific knowledge and through an appropriate clinical environment to develop his/her cardiological clinical skills. The first must be the objective of the subspecialty of cardionephrology (or nephrocardiology) and the second must be the result of collaboration with cardiologists (and other specialists) in cardiorenal care units. This review will first consider various aspects of the challenges that renocardiac syndromes pose to nephrologists and, then, will discuss those aspects of cardionephrology and cardiorenal units that can facilitate an effective response to the challenges.
- Published
- 2022
4. Estimation of glomerular filtration rate in cardiorenal patients: a step forward.
- Author
-
Quiroga, Borja and Díez, Javier
- Subjects
- *
GLOMERULAR filtration rate , *DISEASE risk factors , *CYSTATIN C , *CHRONIC kidney failure , *SODIUM-glucose cotransporter 2 inhibitors - Abstract
The progressive reduction in estimated glomerular filtration rate (eGFR) resulting in chronic kidney disease (CKD) is associated with increased risk of cardiovascular disease (CVD) (i.e. cardiorenal disease). Cardiorenal disease is associated with poor outcomes, mainly due to increased cardiovascular (CV) complications and CV death. Data from general population–based studies and studies of cohorts with CKD and/or CVD show that compared with creatinine-based eGFR, cystatin C–based eGFR and creatinine plus cystatin C–based eGFR detect higher risks of adverse CV outcomes and add predictive discrimination to current CVD risk scores. On the other hand, growing clinical evidence supports kidney and CV protective effects of sodium–glucose cotransporter-2 (SGLT2) inhibitors in cardiorenal patients. However, recent data suggest that some detrimental effects of SGLT2 inhibitors on skeletal muscle mass may lead to overestimation of creatinine-based eGFR and subsequent misinterpretation of associated CV risk in patients treated with these agents. Within this framework, we suggest the advisability of using cystatin C and/or creatinine plus cystatin C–based eGFR for routine clinical practice in cardiorenal patients to more accurately stratify CV risk and evaluate the kidney and CV protective effects of SGLT2 inhibitors. In this regard, we make a call to action to investigate the protective effects of these pharmacological agents using cystatin C–based eGFR. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Humoral Response to Third Dose of SARS-CoV-2 Vaccines in the CKD Spectrum
- Author
-
Quiroga, Borja, Soler, María José, Ortiz, Alberto, Orero, Esther, Tejedor, Sandra, Mantecón, Carlos Jesús Jarava, Gómez Pérez, Virginia Olinda, Marín Franco, Antonio José, Alfaro Sánchez, Christian, Puerta Carretero, Marta, Jaldo Rodríguez, María Teresa, Carnerero Di Riso, Manuel Antonio, Martínez, Shaira, González, Carmen Calderón, Cervienka, Michal, Macías Carmona, Nicolás, Arroyo, David, Pérez Del Valle, Katia M, de Arriba, Gabriel, Mazuecos, Auxiliadora, Cazorla, Juan Manuel, Pereira, Mónica, González Parra, Emilio, Sánchez Márquez, María Gabriela, Lancho Novillo, Carolina, Toyos Ruiz, Carmen, Aguilar Cervera, María Cinta, Muñoz Ramos, Patricia, Sánchez Horrillo, Ana, Jimeno Martín, Isabel, Toapanta, Néstor, Cigarrán Guldris, Secundino, Folgueiras López, Montserrat, Valero San Cecilio, Rosalía, Villacorta Linaza, Blanca, Minguela Pesquera, Ignacio, Santana Estupiñán, Raquel, Zamora, Rocío, Soriano, Sagrario, Muñoz de Bustillo, Eduardo, Pizarro Sánchez, María Soledad, Martínez Puerto, Ana Isabel, Yugueros, Alejandra, Muñiz Pacios, Laura, Leyva, Alba, Rojas, José, Gansevoort, Ron T, de Sequera, Patricia, SENCOVAC collaborative network, Cardiovascular Centre (CVC), and Groningen Kidney Center (GKC)
- Subjects
Transplantation ,hemodialysis ,COVID-19 Vaccines ,Epidemiology ,SARS-CoV-2 ,Vaccination ,COVID-19 ,kidney transplantation ,Critical Care and Intensive Care Medicine ,vaccination ,Antibodies, Viral ,Immunity, Humoral ,peritoneal dialysis ,Nephrology ,Renal Dialysis ,Research Letter ,Humans ,anti-Spike ,Renal Insufficiency, Chronic ,chronic kidney disease - Published
- 2022
6. Artículo especial por el Día Mundial del Riñón: Las sociedades científicas españolas ante la guía ESC 2021 de prevención de la enfermedad vascular: generalizar la medida de la albuminuria para identificar el...
- Author
-
Ortiz, Alberto, Quiroga, Borja, Díez, Javier, Escalada San Martín, Francisco Javier, Ramirez, Leblic, Pérez Maraver, Manuel, Martínez-Berganza Asensio, M. Lourdes, Arranz Arija, José Ángel, Alvarez-Ossorio Fernández, José Luis, Córdoba, Raúl, Brotons Muntó, Franscisco, Cancelo Hidalgo, María Jesús, Carles Reverter, Joan, Plasencia-Rodríguez, Chamaida, Carretera Gómeza, Juana, Guijarro, Carlos, Freijo Guerrero, M. del Mar, and de Sequera, Patricia
- Abstract
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
7. From cardiorenal syndromes to cardionephrology: a reflection by nephrologists on renocardiac syndromes.
- Author
-
Quiroga, Borja, Ortiz, Alberto, Navarro-González, Juan F, Santamaría, Rafael, Sequera, Patricia de, and Díez, Javier
- Subjects
- *
CARDIO-renal syndrome , *NEPHROLOGISTS , *HEART diseases , *SCIENTIFIC knowledge , *CLINICAL competence - Abstract
Cardiorenal syndromes (CRS) are broadly defined as disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other. CRS are currently classified into five categories, mostly based on disease-initiating events and their acuity or chronicity. CRS types 3 and 4 (also called renocardiac syndromes) refer to acute and chronic kidney dysfunction resulting in acute and chronic heart dysfunction, respectively. The notion of renocardiac syndromes has broadened interest in kidney–heart interactions but uncertainty remains in the nephrological community's understanding of the clinical diversity, pathophysiological mechanisms and optimal management approaches of these syndromes. This triple challenge that renocardiac syndromes (and likely other cardiorenal syndromes) pose to the nephrologist can only be faced through a specific and demanding training plan to enhance his/her cardiological scientific knowledge and through an appropriate clinical environment to develop his/her cardiological clinical skills. The first must be the objective of the subspecialty of cardionephrology (or nephrocardiology) and the second must be the result of collaboration with cardiologists (and other specialists) in cardiorenal care units. This review will first consider various aspects of the challenge s that renocardiac syndromes pose to nephrologists and, then, will discuss those aspects of cardionephrology and cardiorenal units that can facilitate an effective response to the challenges. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Infectious consequences of the AKI-to-CKD transition.
- Author
-
Horrillo, Ana Sánchez, Villanueva, Laura Salanova, Cárdenas, Alicia Cabrera, Ramos, Patricia Muñoz, Ortiz, Alberto, and Quiroga, Borja
- Subjects
ACUTE kidney failure ,HIV ,PRIMARY immunodeficiency diseases ,GLOMERULAR filtration rate ,EPIDERMAL growth factor receptors - Abstract
Background Acute kidney injury (AKI) is associated with short- and long-term complications but the consequences of the AKI-to-CKD transition are still poorly understood. We aimed to evaluate the association between the AKI-to-CKD transition and the long-term risk of infection. Methods This retrospective study included patients admitted in a tertiary hospital with community-acquired AKI in 2013 and 2014 who had their estimated glomerular filtration rate (eGFR) assessed at 3 months (±2 weeks) after serum creatinine peaked in the AKI episode. Key exclusion criteria were baseline CKD or confounding factors (active neoplasia, primary immunodeficiency, human immunodeficiency virus, immunosuppressive drugs). The association between the AKI-to-CKD transition (defined as an eGFR <60 ml/min/1.73 m
2 at 3 months) and long-term infections (defined using clinical features, blood/urine analysis, cultures and imaging) was assessed during a follow-up of 9 months (range 2–56). Results Among the 1731 patients admitted with AKI, 367 (21%) were included in the present analysis (64% male, 71 ± 15 years). Three months after AKI, 159 (43%) developed AKI-to-CKD transition. Baseline and post-AKI eGFR were independent predictors of AKI-to-CKD transition [hazard ratio (HR) 0.97, P = .044 and HR 0.96, P < .001, respectively]. During follow-up, 153 (42%) patients developed an infection. Factors associated with infection were older age, cognitive impairment, lower post-AKI eGFR, eGFR loss from baseline to 3 months and AKI-to-CKD transition. Adjusted Cox regression showed that baseline eGFR, 3-month eGFR, eGFR loss and AKI-to-CKD transition were independent predictors of the long-term risk of infection. Conclusions The AKI-to-CKD transition independently predicts the long-term risk of infection following an episode of AKI. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Oral Anticoagulation in Patients with Chronic Kidney Disease and Non-Valvular Atrial Fibrillation: The FAERC Study.
- Author
-
Montomoli, Marco, Roca, Lourdes, Rivera, Mariana, Fernandez-Prado, Raul, Redondo, Beatriz, Camacho, Rosa, Moyano, Cayetana, Pampa, Saul, Gonzalez, Angela, Casas, Juan, Kislikova, Maria, Sanchez Horrillo, Ana, Cabrera Cárdena, Alicia, Quiroga, Borja, Rabasco, Cristina, Piqueras, Sara, Suso, Andrea, Reque, Javier, Villa, Juan, and Ojeda, Raquel
- Subjects
HEMORRHAGE risk factors ,CHRONIC kidney failure complications ,EMBOLISM risk factors ,RESEARCH ,GLOMERULAR filtration rate ,PATIENT aftercare ,ISCHEMIA ,SCIENTIFIC observation ,ANTICOAGULANTS ,ATRIAL fibrillation ,RETROSPECTIVE studies ,CLINICS ,RISK assessment ,DESCRIPTIVE statistics ,BENZOPYRANS ,DEATH ,LONGITUDINAL method ,DISEASE risk factors - Abstract
Atrial fibrillation (AF) is the most common arrhythmia in patients with chronic kidney disease (CKD), and its presence is associated with a higher risk of stroke and mortality. Material and Methods: The FAERC study performed a retrospective multicentre analysis of historical cohorts in which data were collected from arrhythmia diagnosis onwards. Results: We analysed a Spanish cohort of 4749 patients with CKD (mean eGFR 33.9 mL/min) followed up in the nephrology clinic, observing a 12.2% prevalence of non-valvular AF. In total, 98.6% of these patients were receiving anticoagulant treatment, mainly with coumarins (79.7%). Using direct-acting oral anticoagulants (DOACs) was associated with fewer cerebrovascular events than using acenocoumarol, but in contrast with other studies, we could not corroborate the association of risk of bleeding, coronary events, or death with a type of anticoagulant prescribed. Conclusions: Atrial fibrillation is highly prevalent in renal patients. Direct-acting anticoagulants seem to be associated with fewer ischemic-embolic complications, with no differences in bleeding, coronary events, or mortality rates. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Update of the prevention and isolation measure recommendations against SARS-COV-2 in dialysis units of Spain: A position paper of the Spanish Society of Nephrology Council.
- Author
-
de Sequera, Patricia, Quiroga, Borja, and Goicoechea, Marian
- Abstract
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2022
- Full Text
- View/download PDF
11. Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis.
- Author
-
Quiroga, Borja, Soler, María José, Ortiz, Alberto, Gansevoort, Ron T., Leyva, Alba, Rojas, José, and de Sequera, Patricia
- Subjects
COVID-19 vaccines ,HUMORAL immunity ,PERITONEAL dialysis ,ANTIBODY titer ,HEMODIALYSIS patients - Abstract
Introduction. Patients on peritoneal dialysis (PD) present an impaired humoral response against SARS-CoV-2, at least after the initial vaccination and booster dose. Until now, the effect of a fourth dose has not been established. The aim of the present study is to evaluate the long-term dynamics of the humoral response of PD patients to multiple doses of SARS-CoV-2 vaccines, focusing on the effect of the fourth dose. Methods. This is an analysis of the prospective and multicentric SENCOVAC study. We included patients on PD without additional immunosuppression that had received at least 3 SARS-CoV-2 mRNA vaccine doses. We evaluated anti-spike antibody titers after the initial vaccination, third and fourth doses, using prespecified fixed assessments (i.e., baseline, 28 days, 3, 6, and 12 months after completing the initial vaccine schedule). Breakthrough infections were also collected. Results. We included 164 patients on PD (69% males, 62 ± 13 years old). In patients who had received only two doses, the rates of positive humoral response progressively decreased from 96% at 28 days to 80% at 6 months, as did with anti-spike antibody titers. At 6 months, 102 (62%) patients had received the third vaccine dose. Patients with the third dose had higher rates of positive humoral response (p = 0.01) and higher anti-spike antibody titers (p < 0.001) at 6 months than those with only 2 doses. At 12 months, the whole cohort had received 3 vaccine doses, and 44 (27%) patients had an additional fourth dose. The fourth dose was not associated to higher rates of positive humoral response (100 vs. 97%, p = 0.466) or to statistically significant differences in anti-spike antibody titers as compared to three doses (p = 0.371) at 12 months. Prior antibody titers were the only predictor for subsequent higher anti-spike antibody titer (B 0.53 [95%CI 0.27–0.78], p < 0.001). The 2 (1.2%) patients that developed COVID-19 during follow-up had mild disease. Conclusions. PD presents an acceptable humoral response with three doses of SARS-CoV-2 vaccines that improve the progressive loss of anti-spike antibody titers following two vaccine doses. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Predictores de eventos clínicos en una cohorte de pacientes con enfermedad de Fabry en tratamiento sustitutivo enzimático
- Author
-
Goicoechea, Marian, Gomez Preciado, Francisco, Benito, Silvia, Torras Ambròs, Joan, Torra, Roser, Huerta, Ana, Restrepo, Alejandra, Ugalde, Jessica, Astudillo, Daniela Estefania, Agraz, Irene, Lopez Mendoza, Manuel, Arriba, Gabriel de, Corchete, Elena, Quiroga, Borja, Gutierrez, Maria Jose, Martin Conde, Maria Luisa, Lopes, Vanessa, Ramos, Carmela, Mendez, Irene, Cao, Mercedes, Dominguez, Fernando, Ortiz, Alberto, Spanish Group for the Study of Glomerular Diseases (GLOSEN), Spanish Group for the Study of Glomerular Diseases (GLOSEN), Institut Català de la Salut, [Goicoechea M] Servicio de Nefrología Hospital General Universitario Gregorio Marañon, Spain. Red de Investigación Renal (REDinRen), Fondos FEDER, Spain. [Gomez-Preciado F] Servicio de Nefrología Hospital Universitario de Bellvitge, Spain. [Benito S] Servicio de Nefrología Fundacion Puigvert, Spain. [Torras J] Red de Investigación Renal (REDinRen), Fondos FEDER, Spain. Servicio de Nefrología Hospital Universitario de Bellvitge, Spain. [Torra R] Red de Investigación Renal (REDinRen), Fondos FEDER, Spain. Servicio de Nefrología Fundacion Puigvert, Spain. [Huerta A] Servicio de Nefrología Hospital Universitario Puerta del Hierro Majadahonda, Spain. [Agraz I] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
0301 basic medicine ,Male ,Fabry's disease ,030232 urology & nephrology ,030105 genetics & heredity ,chemistry.chemical_compound ,0302 clinical medicine ,Clinical trials ,Chronic kidney disease ,Medicine ,terapéutica::farmacoterapia::terapia enzimática::tratamiento de sustitución enzimática [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Tratamiento enzimático sustitutivo ,Otros calificadores::/terapia [Otros calificadores] ,Kidney diseases ,Renal events ,Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Cerebrovascular Disorders::Cerebral Small Vessel Diseases::Fabry Disease [DISEASES] ,Incidence (epidemiology) ,Enfermedad de Fabry ,Enzyme replacement therapy ,Middle Aged ,Enzymes ,Nephrology ,Creatinine ,Cohort ,Female ,Adult ,medicine.medical_specialty ,Eventos renales ,enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::enfermedades cerebrales metabólicas::enfermedades cerebrales metabólicas congénitas::enfermedades por almacenamiento lisosómico del sistema nervioso::esfingolipidosis::enfermedad de Fabry [ENFERMEDADES] ,03 medical and health sciences ,Malaltia de Fabry ,Internal medicine ,Albumins ,Humans ,Enzyme Replacement Therapy ,Renal Insufficiency, Chronic ,Enfermedad renal crónica ,Retrospective Studies ,Fabry disease ,business.industry ,Proportional hazards model ,Enzims - Ús terapèutic ,diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,Other subheadings::/therapy [Other subheadings] ,medicine.disease ,Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Diseases of the genitourinary system. Urology ,Log-rank test ,chemistry ,Avaluació de resultats (Assistència sanitària) ,Malalties del ronyó ,Fabry Disease ,RC870-923 ,Enzims ,business ,Ronyons - Malalties - Tractament ,Therapeutics::Drug Therapy::Enzyme Therapy::Enzyme Replacement Therapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,Kidney disease ,Assaigs clínics - Abstract
Enfermedad de Fabry; Enfermedad renal crónica; Tratamiento enzimático sustitutivo Fabry disease; Chronic kidney disease; Enzyme replacement therapy Malaltia de Fabry; Malaltia renal crònica; Tractament enzimàtic substitutiu Fabry disease may be treated by enzyme replacement therapy (ERT), but the impact of chronic kidney disease (CKD) on the response to therapy remains unclear. The aim of the present study was to analyse the incidence and predictors of clinical events in patients on ERT. Study design: Multicentre retrospective observational analysis of patients diagnosed and treated with ERT for Fabry disease. The primary outcome was the first renal, neurological or cardiological events or death during a follow-up of 60 months (24-120). Results: In 69 patients (42 males, 27 females, mean age 44.6±13.7 years), at the end of follow-up, eGFR and the left ventricular septum thickness remained stable and the urinary albumin: creatinine ratio tended to decrease, but this decrease only approached significance in patients on agalsidase-beta (242-128mg/g (p=0.05). At the end of follow-up, 21 (30%) patients had suffered an incident clinical event: 6 renal, 2 neurological and 13 cardiological (including 3 deaths). Events were more frequent in patients with baseline eGFR≤60ml/min/1.73m2 (log Rank 12.423, p=0.001), and this remained significant even after excluding incident renal events (log Rank 4.086, p=0.043) and in males and in females. Lower baseline eGFR was associated with a 3- to 7-fold increase the risk of clinical events in different Cox models. Conclusions: GFR at the initiation of ERT is the main predictor of clinical events, both in males and in females, suggesting that start of ERT prior to the development of CKD is associated with better outcomes. El objetivo de este estudio es realizar un mapa del tratamiento actual de la enfermedad de Fabry en España, analizando el efecto de diferentes factores en el desarrollo de eventos clínicos a largo plazo. Diseño del estudio: Análisis observacional retrospectivo multicéntrico. Criterios de inclusión: pacientes diagnosticados y tratados de enfermedad de Fabry. Se recogieron datos generales en relación con el diagnóstico, síntomas y tipo mutación, tipo de tratamiento recibido, evolución renal y cardiológica. Durante un tiempo de seguimiento de 60 meses (24-120), se recogió el primer evento clínico tras el inicio de tratamiento sustitutivo enzimático definido como mortalidad, evento renal, cardiológico o neurológico. Resultados: Se incluyeron 69 pacientes (42 H, 27 M) con una edad media de 44,6 ± 13,7 años. A los cinco años de tratamiento, el FGe y la hipertrofia ventricular izquierda se mantuvieron estables, y la albuminuria tiende a disminuir, siendo este descenso más significativo en el grupo de pacientes tratados con beta-galactosidasa (de 242 a 128mg/g (p = 0,05). Veintiún pacientes sufrieron un evento clínico (30%): seis renales, dos neurológicos y 13 cardiológicos (incluidas tres muertes). Los pacientes con ERC (FGe < 60) antes del inicio de tratamiento tuvieron más eventos (log-rank 12.423, p = 0,001), manteniéndose la predicción si excluíamos los eventos renales (log-rank 4.086 (p = 0,043) en hombres y mujeres. La peor función renal al inicio del tratamiento aumentó entre tres y siete veces el riesgo de eventos clínicos en diferentes modelos de Cox ajustados. Conclusiones: La función renal al inicio de tratamiento sustitutivo enzimático es la principal predictora de desarrollo de eventos clínicos a largo plazo, tanto en hombres como mujeres. El inicio de tratamiento sustitutivo enzimático precoz antes del desarrollo de ERC mejoraría el pronóstico. MG, JT, AO, RT are supported by ISCIII RETIC REDINREN, RD016/009 and FEDER funds
- Published
- 2021
13. Position statement of the Spanish Society of Nephrology on the SARS-CoV-2 vaccines.
- Author
-
Sánchez-Álvarez, Emilio, Quiroga, Borja, and de Sequera, Patricia
- Abstract
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
14. Consulta monográfica de onconefrología. Justificación y puesta en marcha.
- Author
-
Alonso, Fabiola, Auñón, Pilar, Cavero, Teresa, Salgueira, Mercedes, Praga, Manuel, Quiroga, Borja, de Francisco, Ángel L. M., and Macía, Manuel
- Abstract
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
15. Ferroterapia en el manejo de la anemia en la enfermedad renal crónica no en diálisis: perspectiva del grupo de anemia de la S.E.N.
- Author
-
Cases, Aleix, Jesús Puchades, Maria, de Sequera, Patricia, Quiroga, Borja, Martin-Rodriguez, Leyre, Luis Gorriz, José, and Portolés, José
- Abstract
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2021
- Full Text
- View/download PDF
16. Efectividad y seguridad del uso de inhibidores de PCSK9 en el tratamiento de la dislipidemia en el paciente con insuficiencia renal.
- Author
-
Quiroga, Borja, Muñoz Ramos, Patricia, and Álvarez Chiva, Vicente
- Abstract
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2020
- Full Text
- View/download PDF
17. The effect of some medications given to CKD patients on vitamin D levels
- Author
-
Yuste, Claudia, Quiroga, Borja, García de Vinuesa, Soledad, Goicoechea, Maria Angeles, Barraca, Daniel, Verdalles, Ursula, and Luño, Jose
- Subjects
Inhibidores RAS ,Chronic kidney disease ,Allopurinol ,Vitamina D ,RAS inhibitors ,Statins ,Vitamin D ,Enfermedad renal crónica ,Estatinas ,Alopurinol - Abstract
Background: Vitamin D deficiency and polypharmacy is a common problem over chronic kidney disease (CKD) population. Objectives: To assess the clinical and analytical characteristics of CKD patients with 25-OH-D3 deficiency (
- Published
- 2015
18. Impacto de la aplicación del 8.° JNC y de las guías KDIGO-2013 en el control de la hipertensión arterial y los lípidos en una consulta de Nefrología.
- Author
-
Galán, Isabel, Verdalles, Úrsula, De Vinuesa, Marisol García, Quiroga, Borja, Goicoechea, Marian, Pérez, Ana, Verde, Eduardo, and Luño, José
- Abstract
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2018
- Full Text
- View/download PDF
19. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
- Author
-
Goicoechea, Marian, de Vinuesa, Soledad García, Quiroga, Borja, Verde, Eduardo, Bernis, Carmen, Morales, Enrique, Fernández-Juárez, Gema, de Sequera, Patricia, Verdalles, Ursula, Delgado, Ramón, Torres, Alberto, Arroyo, David, Abad, Soraya, Ortiz, Alberto, and Luño, José
- Abstract
Background: Patients with chronic kidney disease (CKD) are at high risk for developing cardiovascular events. However, limited evidence is available regarding the use of aspirin in CKD patients to decrease cardiovascular risk and to slow renal disease progression.Study Design: Prospective, multicenter, open-label randomized controlled trial.Setting and Participants: One hundred eleven patients with estimated glomerular filtration rate (eGFR) 15-60 ml/min/1.73 m
2 without previous cardiovascular events.Intervention: Aspirin treatment (100 mg/day) (n = 50) or usual therapy (n = 61). Mean follow-up time was 64.8 ± 16.4 months.Outcomes: The primary endpoint was composed of cardiovascular death, acute coronary syndrome (nonfatal MI, coronary revascularization, or unstable angina pectoris), cerebrovascular disease, heart failure, or nonfatal peripheral arterial disease. Secondary endpoints were fatal and nonfatal coronary events, renal events (defined as doubling of serum creatinine, ≥ 50% decrease in eGFR, or renal replacement therapy), and bleeding episodes.Results: During follow-up, 17 and 5 participants suffered from a primary endpoint in the control and aspirin groups, respectively. Aspirin did not significantly reduce primary composite endpoint (HR, 0.396 (0.146-1.076), p = 0.069. Eight patients suffered from a fatal or nonfatal coronary event in the control group compared to no patients in the aspirin group. Aspirin significantly reduced the risk of coronary events (log-rank, 5.997; p = 0.014). Seventeen patients in the control group reached the renal outcome in comparison with 3 patients in the aspirin group. Aspirin treatment decreased renal disease progression in a model adjusted for age, baseline kidney function, and diabetes mellitus (HR, 0.272; 95% CI, 0.077-0.955; p = 0.043) but did not when adjusted for albuminuria. No differences were found in minor bleeding episodes between groups and no major bleeding was registered.Limitations: Small sample size and open-label trial.Conclusions: Long-term treatment with low-dose aspirin did not reduce the composite primary endpoint; however, there were reductions in secondary endpoints with fewer coronary events and renal outcomes.ClinicalTrials.gov Identifier: NCT01709994. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
20. Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients.
- Author
-
Goicoechea, Marian, Sanchez-Niño, Maria Dolores, Ortiz, Alberto, García de Vinuesa, Soledad, Quiroga, Borja, Bernis, Carmen, Morales, Enrique, Fernández-Juarez, Gema, de Sequera, Patricia, Verdalles, Ursula, Verde, Eduardo, and Luño, José
- Abstract
Background Resolution of inflammation is regulated by endogenous lipid mediators, such as lipoxins and their epimers, including 15-epi-lipoxin A4 (15-epi-LXA4). However, there is no information on 15-epi-LXA4 and its in vivo regulation in chronic kidney disease (CKD) patients. Study design Open label randomized clinical trial. Setting and participants 50 participants with chronic kidney disease (CKD) stage 3 and 4 without prior cardiovascular disease (25 in the aspirin group and 25 in the standard group) followed for 46 months. Intervention Aspirin (100 mg/day) or standard treatment. Aim To analyze the effect of aspirin on plasma 15-epi-LXA4 levels and inflammatory markers in CKD patients. Results Baseline plasma15-epi-LXA4 levels were lower in diabetic (1.22 ± 0.99 ng/ml) than in non-diabetic CKD patients (2.05 ± 1.06 ng/ml, p < 0.001) and inversely correlated with glycosylated hemoglobin levels (r = −0.303, p = 0.006). In multivariate analysis, diabetes was associated with lower 15-epi-LXA4 levels, adjusted for age, inflammatory markers and renal function (p = 0.005). In the whole study population, 15-epi-LXA4 levels tended to increase, but not significantly (p = 0.45), after twelve months on aspirin (from mean ± SD 1.84 ± 1.06 to 2.04 ± 0.75 ng/ml) and decreased in the standard care group (1.60 ± 1.15 to 1.52 ± 0.68 ng/ml, p = 0.04). The aspirin effect on 15-epi-LXA4 levels was more striking in diabetic patients, increasing from 0.94 ± 0.70 to 1.93 ± 0.74 ng/ml, p = 0.017. Conclusions Diabetic patients with CKD have lower circulating 15-epi-LXA4 levels than non-diabetic CKD patients. Low dose aspirin for 12 months increased 15-epi-LXA4 levels in diabetic patients. Given its anti-inflammatory properties, this increase in 15-epi-LXA4 levels may contribute to the beneficial effects of low dose aspirin. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
21. Prevalencia y características de los pacientes con hipertensión arterial resistente y enfermedad renal crónica.
- Author
-
Verdalles, Úrsula, Goicoechea, Marian, de Vinuesa, Soledad Garcia, Quiroga, Borja, Galan, Isabel, Verde, Eduardo, de Jose, Ana Perez, and Luño, José
- Abstract
Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2016
- Full Text
- View/download PDF
22. Interarm systolic blood pressure as a predictor of cardiovascular events in patients with chronic kidney disease.
- Author
-
Quiroga, Borja, Galán, Isabel, de Vinuesa, Soledad García, Goicoechea, Marian, Verdalles, Úrsula, and Luño, José
- Subjects
- *
SYSTOLIC blood pressure , *CARDIOVASCULAR diseases , *KIDNEY diseases , *FOLLOW-up studies (Medicine) , *GLOMERULAR filtration rate , *PATIENTS - Abstract
Background. Increased interarm systolic blood pressure difference (IASBPD) is associated with mortality and cardiovascular (CV) events both in the general population and in patients at high CV risk. The aim of the present study was to assess the value of IASBPD ≥ 10 mmHg for predicting CV events in patients with chronic kidney disease (CKD). Methods. The study sample comprised 652 patients with CKD (age 67 ± 15 years, 58.1% men). Follow-up was 19 ± 5 months. We recorded increased IASBPD and related factors and assessed the predictive value of this variable for CV events. Results. We recorded diabetes mellitus in 136 patients (20.8%), history of CV disease in 213 (32.6%) and dyslipidaemia in 327 (50.1%). The mean glomerular filtration rate was 45.9 ± 18.9 mL/min/1.73 m², and the median albumin/creatinine ratio was 26(0-151) mg/g. IASBPD was ≥10 mmHg in 184 patients (28.1%). The factors associated with IASBPD ≥10 mmHg were age, systolic blood pressure levels, history of congestive heart failure, lower levels of high-density lipid cholesterol and higher use of hypertensive drugs. Fifty-eight patients (8.5%) developed a CV event during the follow-up. IASBPD ≥10 mmHg [HR, 1.802, 95%CI (1.054-3.079); P = 0.031] was an independent predictor of CV events. Conclusions. Increased IASBPD is an independent predictor of CV events in CKD patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
23. Intraindividual Interleukin-6 Variations on the Cardiovascular Prognosis of Patients with Chronic Renal Disease.
- Author
-
Goicoechea, Marian, Quiroga, Borja, García de Vinuesa, Soledad, Verdalles, Úrsula, Reque, Javier, Panizo, Nayara, Arroyo, David, Santos, Alba, Macías, Nicolás, and Luño, José
- Subjects
- *
INTERLEUKIN-6 , *CHRONIC kidney failure , *CARDIOVASCULAR diseases , *INFLAMMATION , *HEALTH outcome assessment , *TUMOR necrosis factors , *C-reactive protein , *DIALYSIS (Chemistry) , *PROGNOSIS - Abstract
In chronic kidney disease (CKD) patients on dialysis, plasma interleukin (IL)-6 levels predict mortality better than other markers. Impact of intraindividual changes of inflammatory markers on cardiovascular (CV) events in CKD patients is unknown. The aim of this study is to demonstrate the relation between CV outcomes and variations of C-reactive protein (CRP), IL-6, IL-1 β, and tumor necrosis factor (TNF)- α in CKD. Ninety patients (mean age: 68.5 ± 12.8 years) at different stages (1-4) of CKD were evaluated. Serum CRP, IL-6, IL-1 β, and TNF- α were measured basally and after taking statins or angiotensin II receptor blockers. Three patterns were defined for each marker (baseline, mean of two measurements, and variation of the marker: increase or decrease after 6 months). During follow-up (mean time: 72.7 ± 19.8 months), 14 patients died, 11 were included on dialysis program, and 29 suffered a CV event. Patients with persistently elevated IL-6 values had higher risk to develop CV events [OR = 1.21 (1.11-1.32), p = 0.001]. Mean of two measurements of IL-6 was a better predictor for events than a single measurement of IL-6, CRP, TNF- α, and IL-1 β. A mean of two determinations of plasma IL-6 greater than 6 pg/mL and previous peripheral vascular disease was related to an increased risk for CV events [2.34 (1.05-5.22), p = 0.037 and 2.95 (1.27-6.93), p = 0.011, respectively] in an adjusted Cox regression model. IL-6 is a better inflammatory marker than CRP, TNF- α, and IL1 β at predicting CV events in CKD nondialysis patients. Mean of two measurements is better than simple determinations at predicting CV outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.